Clareo Health | An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of symptomatic multiple myeloma as defined by International Myeloma Working Group (IMWGURC).
Phase 1: Relapsed or relapsed/refractory myeloma after at least 1 previous treatments and with a life expectancy of more than 3 months.
Phase 2: Measurable (as defined by IMWGURC) disease after at least 1 previous treatment.
You may not be if
History of allogeneic stem cell transplant.
Phase 2 only: Prior bortezomib therapy will only be allowed if there was a demonstrated positive response, and disease progression occurred off therapy.
Must have not experienced significant blood level changes, e.g. very low platelets, while on previous bortezomib therapy
Prior radiation therapy to \> 25% of the bone marrow (whole pelvis is 25%).
